Fibroid is a frequent pathology of infertile women. Its deleterious effect on the infertility would be due to the mechanical way. The interest of the resection of intramural fibroids is discussed. It is necessary to measure the indication of a myomectomy, whatever the surgical procedure. On the one hand, it may cause important potential complications, and on the other hand, the surgery does not improve the parameters of the fertility. Thus, it is a major stake to avoid the surgical operation. A decrease of the size of these fibroids by medical treatment is then a good option. When the surgical treatment is necessary, a medical pre-surgical treatment is often proposed in order to decrease the symptomatology and to reduce the size of the fibroid to facilitate the surgery. Acetate Ulipristal (UPA) has been marketed in this indication. Following the Pearl I-II studies, the first indication in France was a pre-surgical treatment for 3 months at a dose of 5 mg per day. The Pearl III and IV studies evaluated the Esmya® administration as a long-term intermittent repeated treatment, giving to it a prominent position for the long-term management of symptomatic fibroids. Furthermore, cases of pregnancy before surgery are frequently described in women with fibroids treated by UPA for a pre-IVF surgery. 5 to 10 % of women who are managed for infertility have fibroids and only 2% to 3% have this unique cause of infertility. Then, some of patients followed in ART centers have been treated by UPA to reduce the fibroids size and/or to decrease the associate symptoms. The aim of this study is to evaluate in the different French ART centers, the impact on fertilization of UPA administration for infertile women with fibroids and to describe the modalities of its prescriptions and to collect information regarding safety tolerance profile of Esmya® in this patient population.
A retrospective, national, multicenter study
Study Type
OBSERVATIONAL
Enrollment
127
Ulipristal Acetate (Esmya) administrated for fibroids indication before surgery and IVF/ICSI procedure(retrospective study)
Chu Angers
Angers, France
Chu Besancon
Besançon, France
Chu Pellegrin
Bordeaux, France
Polyclinique Jean Villar
Bruges, France
Centre Hospitalier Intercommunal Creteil
Créteil, France
Chu Dijon
Dijon, France
Clinique Val D'Ouest
Écully, France
Chru Lille
Lille, France
Cpma Marseille
Marseille, France
Imr Rocca
Marseille, France
...and 13 more locations
Clinical pregnancy
Clinical pregnancy rate after maximum 4 embryos transferred by IVF/ICSI procedures ; pregnancy is defined by beta-hCG\> 1000 or presence of a gestation sac
Time frame: 15 days
Spontaneous pregnancy
Spontaneous pregnancy rate before first embryo transferred by IVF/ICSI procedures; pregnancy is defined by beta-hCG \> 1000 or presence of a gestation sac
Time frame: at least 2 months
Live birth / miscarriage
Live birth rate / miscarriage rate
Time frame: 9 months
Fibroids size
Fibroids size reduction
Time frame: Baseline (before ulipristal acetate administration) and 20 months
Surgery rate
Rate of surgery
Time frame: 3 months
Surgery description
Description of the surgery type and surgery indication
Time frame: 3 months
Description of ulipristal acetate prescription
Reasons of the prescription, type of fibroids concerned, number of cycles of treatment, treatment duration
Time frame: 20 months
Safety impact on ulipristal acetate administration
Review of adverse drug reactions resulting in ulipristal acetate treatment modification or discontinuation
Time frame: 20 months
Ulipristal acetate safety analysis in infertile women with fibroids
Review of all serious adverse reactions (expected or unexpected) in this population
Time frame: 20 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.